Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, bilateral breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaActive, not recruitingPhase 12026-07-31NCT04052555

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Farmington Health CenterFarmingtonUnited States62
Huntsman Cancer Institute/University of UtahSalt Lake CityUnited States249
Mayo Clinic Hospital in ArizonaPhoenixUnited States120
Mayo Clinic in ArizonaScottsdaleUnited States191
Mayo Clinic in FloridaJacksonvilleUnited States224
Mayo Clinic in RochesterRochesterUnited States687
NYP/Weill Cornell Medical CenterNew YorkUnited States128
Ohio State University Comprehensive Cancer CenterColumbusUnited States548
Rutgers Cancer Institute of New JerseyNew BrunswickUnited States223
University of California Davis Comprehensive Cancer CenterSacramentoUnited States299
University of Texas Medical BranchGalvestonUnited States43
University of Utah Sugarhouse Health CenterSalt Lake CityUnited States52
University of Wisconsin Carbone Cancer Center - University HospitalMadisonUnited States249
UPMC Hillman Cancer CenterPittsburghUnited States330